Long-term follow-up of mycobacterium avium complex lung disease in patients treated with regimens including clofazimine and/or rifampin

Chest

Volumn 149, Issue 5, 2016, Pages 1285-1293

  Jarand, Julie ^a   Paul Davis, J ^a   Cowie, Robert L ^a   Field, Stephen K ^a   Fisher, Dina A ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Clofazimine; Mycobacterium avium complex; Nontuberculous mycobacteria

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; CLOFAZIMINE; ETHAMBUTOL; RIFAMPICIN; ANTIINFECTIVE AGENT; MACROLIDE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BRONCHIECTASIS; COHORT ANALYSIS; CONTROLLED STUDY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HALLUCINATION; HUMAN; KIDNEY DISEASE; LUNG CAVITATION; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOBACTERIOSIS; MYCOBACTERIUM AVIUM COMPLEX LUNG DISEASE; PRIORITY JOURNAL; RASH; RELAPSE; RETREATMENT; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN DISCOLORATION; SPUTUM CULTURE; SPUTUM SMEAR; TREATMENT OUTCOME; COMBINATION DRUG THERAPY; MIDDLE AGED; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; PNEUMONIA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLOFAZIMINE; DRUG THERAPY, COMBINATION; ETHAMBUTOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MACROLIDES; MALE; MIDDLE AGED; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; PNEUMONIA; RETROSPECTIVE STUDIES; RIFAMPIN;

EID: 84966665289     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.15-0543     Document Type: Article

References (36)

1. Hoefsloot W, van Ingen J, Andrejak C, et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J. 2013;42(6):1604-1613.
2. Thomson R, Tolson C, Carter R, Coulter C, Huygens F, Hargreaves M. Isolation of nontuberculous mycobacteria (NTM) from household water and shower aerosols in patients with pulmonary disease caused by NTM. J Clin Microbiol. 2013;51(9):3006-3011.
3. Falkinham JO III. Ecology of nontuberculous mycobacteria-where do human infections come from? Semin Respir Crit Care Med. 2013;34(1):95-102.
4. Falkinham JO III. Nontuberculous mycobacteria from household plumbing of patients with nontuberculous mycobacteria disease. Emerg Infect Dis. 2011;17(3):419-424.
5. Prevots DR, Shaw PA, Strickland D, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med. 2010;182(7):970-976.
6. Thomson RM. Changing epidemiology of pulmonary nontuberculous mycobacteria infections. Emerg Infect Dis. 2010;16(10): 1576-1583.
7. Amorim A, Macedo R, Lopes A, Rodrigues I, Pereira E. Non-tuberculous mycobacteria in HIV-negative patients with pulmonary disease in Lisbon, Portugal. Scand J Infect Dis. 2010;42(8): 626-628.
8. Lee SK, Lee EJ, Kim SK, Chang J, Jeong SH, Kang YA. Changing epidemiology of nontuberculous mycobacterial lung disease in South Korea. Scand J Infect Dis. 2012;44(10): 733-738.
9. Marras TK, Chedore P, Ying AM, Jamieson F. Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997-2003. Thorax. 2007;62(8):661-666.
10. Winthrop KL, McNelley E, Kendall B, et al. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am J Respir Crit Care Med. 2010;182(7):977-982.
11. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(7): 367-416.
12. Kim RD, Greenberg DE, Ehrmantraut ME, et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med. 2008;178(10):1066-1074.
13. Mehta M, Marras TK. Impaired healthrelated quality of life in pulmonary nontuberculous mycobacterial disease. Respir Med. 2011;105(11):1718-1725.
14. Maekawa K, Ito Y, Oga T, et al. Highresolution computed tomography and health-related quality of life in Mycobacterium avium complex disease. Int J Tuberc Lung Dis. 2013;17(6):829-835.
15. Field SK, Fisher D, Cowie RL. Mycobacterium avium complex pulmonary disease in patients without HIV infection. Chest. 2004;126(2):566-581.
16. Griffith DE, Brown BA, Girard WM, Griffith BE, Couch LA, Wallace RJ Jr. Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease. Clin Infect Dis. 2001;32(11):1547-1553.
17. Wallace RJ Jr., Brown BA, Griffith DE, Girard W, Tanaka K. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J Infect Dis. 1995;171(3):747-750.
18. Griffith DE, Brown BA, Girard WM, Wallace RJ Jr. Adverse events associated with high-dose rifabutin in macrolidecontaining regimens for the treatment of Mycobacterium avium complex lung disease. Clin Infect Dis. 1995;21(3):594-598.
19. Field SK, Cowie RL. Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. Chest. 2003;124(4):1482-1486.
20. Roussel G, Igual J; Groupe d'Etude et de Traitement des Infections á Mycobactéries (GETIM). Clarithromycin with minocycline and clofazimine for Mycobacterium avium intracellulare complex lung disease in patients without the acquired immune deficiency syndrome. Int J Tuberc Lung Dis. 1998;2(6):462-470.
21. Olivier KN, Shaw PA, Glaser TS, et al. Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. Ann Am Thorac Soc. 2014;11(1):30-35.
22. American Thoracic Society; Medical Section of the American Lung Association. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med. 1997;156(2 Pt 2):S1-S25.
23. Hayashi M, Takayanagi N, Kanauchi T, Miyahara Y, Yanagisawa T, Sugita Y. Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2012;185(5):575-583.
24. Wallace RJ Jr., Brown-Elliott BA, McNulty S, et al. Macrolide/azalide therapy for nodular/bronchiectatic Mycobacterium avium complex lung disease. Chest. 2014;146(2): 276-282.
25. Wallace RJ Jr., Zhang Y, Brown BA, et al. Polyclonal Mycobacterium avium complex infections in patients with nodular bronchiectasis. Am J Respir Crit Care Med. 1998;158(4):1235-1244.
26. Wallace RJ Jr., Zhang Y, Brown-Elliott BA, et al. Repeat positive cultures in Mycobacterium intracellulare lung disease after macrolide therapy represent new infections in patients with nodular bronchiectasis. J Infect Dis. 2002;186(2): 266-273.
27. Kobashi Y, Matsushima T, Oka M. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir Med. 2007;101(1):130-138.
28. Kobashi Y, Matsushima T. The microbiological and clinical effects of combined therapy according to guidelines on the treatment of pulmonary Mycobacterium avium complex disease in Japan-including a follow-up study. Respiration. 2007;74(4):394-400.
29. Wallace RJ Jr., Brown BA, Griffith DE, Girard WM, Murphy DT. Clarithromycin regimens for pulmonary Mycobacterium avium complex: the first 50 patients. Am J Respir Crit Care Med. 1996;153(6 Pt 1): 1766-1772.
30. Tanaka E, Kimoto T, Tsuyuguchi K, et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med. 1999;160(3):866-872.
31. Jeong BH, Jeon K, Park HY, et al. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2015;191(1):96-103.
32. Chaisson RE, Keiser P, Pierce M, et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. AIDS. 1997;11(3):311-317.
33. Fournier S, Burguiere AM, Flahault A, Vincent V, Treilhou MP, Eliaszewicz M. Effect of adding clofazimine to combined clarithromycin-ethambutol therapy for Mycobacterium avium complex septicemia in AIDS patients. Eur J Clin Microbiol Infect Dis. 1999;18(1):16-22.
34. Griffith DE, Brown-Elliott BA, Shepherd S, McLarty J, Griffith L, Wallace RJ Jr. Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2005;172(2):250-253.
35. van Ingen J, Egelund EF, Levin A, et al. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med. 2012;186(6):559-565.
36. Mitchell JD, Bishop A, Cafaro A, Weyant MJ, Pomerantz M. Anatomic lung resection for nontuberculous mycobacterial disease. Ann Thorac Surg. 2008;85(6):1887-1892.